^
    11d
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P3, N=120, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive
    |
    Epidaza (chidamide) • XNW5004
    11d
    To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors (clinicaltrials.gov)
    P1/2, N=120, Completed, Evopoint Biosciences Inc. | Recruiting --> Completed | N=176 --> 120 | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    EZH2 mutation
    |
    XNW5004
    9ms
    Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=307, Recruiting, Evopoint Biosciences Inc. | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    Xtandi (enzalutamide) • XNW5004
    1year
    A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Evopoint Biosciences Inc.
    New P3 trial
    |
    Epidaza (chidamide) • XNW5004
    1year
    To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Evopoint Biosciences Inc.
    New P2 trial
    |
    XNW5004
    1year
    Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=307, Enrolling by invitation, Evopoint Biosciences Inc.
    New P1/2 trial • Combination therapy • Metastases
    |
    Xtandi (enzalutamide) • XNW5004
    over1year
    To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors (clinicaltrials.gov)
    P1/2, N=176, Recruiting, Evopoint Biosciences Inc.
    New P1/2 trial • Metastases
    |
    XNW5004
    almost2years
    Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (clinicaltrials.gov)
    P1/2, N=204, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • XNW5004
    2years
    Study of XNW5004 Tablet in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (clinicaltrials.gov)
    P1/2, N=204, Not yet recruiting, Evopoint Biosciences Inc.
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • XNW5004
    almost3years
    XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies (AACR 2023)
    In summary, XNW5004 is a potent EZH2 inhibitor with promising efficacy, pharmacokinetic and safety properties. XNW5004 is expected to be a potent therapeutic candidate in cancer treatment and is now in Phase II clinical trial for both liquid and solid tumors.
    Preclinical • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    AR (Androgen receptor) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    EZH2 mutation • AR expression • EZH2 Y641F • EZH2 Y641 • EZH2 overexpression
    |
    XNW5004